Question 1

What is combined oxidative phosphorylation deficiency 51?

Accepted Answer

Combined oxidative phosphorylation deficiency 51 (COXPD51) is a complex multisystem condition that primarily affects energy production in the body. It is caused by variants in the PTCD3 gene, which plays a crucial role in mitochondrial function. The condition typically manifests in infancy or early childhood with significant impacts on growth, neurological function, and respiratory status. Precise prevalence estimates are not well established for this disorder.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 51?

Accepted Answer

The clinical presentation of COXPD51 is marked by a constellation of findings affecting multiple organ systems. Neurologically, individuals exhibit cerebral atrophy, nystagmus, optic atrophy, myoclonus, and rigidity. After a period of apparently typical early development, affected children experience a phase of developmental regression marked by loss of previously acquired skills, underscoring the profound impact on cognitive and motor abilities. In addition, children present with severe short stature, growth delay, small size for gestational age, and intrauterine growth retardation, while respiratory difficulties such as neonatal respiratory distress, respiratory failure, and aspiration pneumonia are consistently observed. Hearing impairment and the need for nasogastric tube feeding further highlight the multisystem involvement. Not all individuals experience every feature, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation deficiency 51?

Accepted Answer

COXPD51 is caused by pathogenic variants in the PTCD3 gene, which is essential for proper mitochondrial function and energy production. The condition is inherited in an autosomal recessive pattern, meaning that an affected individual has inherited one altered copy of the gene from each parent. This inheritance pattern implies that both parents are carriers, and each child has a 25% chance of being affected when both parents carry a pathogenic variant. Genetic counseling is recommended to help families understand the implications and recurrence risks associated with the condition. Associated genes include PTCD3.

Question 4

How is combined oxidative phosphorylation deficiency 51 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 51 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is combined oxidative phosphorylation deficiency 51 diagnosed?

Accepted Answer

The diagnosis of combined oxidative phosphorylation deficiency 51 is confirmed through molecular genetic testing that identifies pathogenic variants in the PTCD3 gene. In addition, clinical evaluation—including assessment of developmental history, growth patterns, and neurological status—and imaging studies to detect cerebral atrophy are important components of the diagnostic process. Because many features of this condition can overlap with other disorders, genetic testing is essential to establish a definitive diagnosis.

Question 6

Are there treatments for combined oxidative phosphorylation deficiency 51?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as no treatments are specifically approved for COXPD51. Treatment is highly individualized and typically involves a multidisciplinary team that may include neurologists, respiratory specialists, nutritionists, and other experts. Regular surveillance is an essential part of long-term care, helping to identify potential complications before they become serious. Families are encouraged to discuss treatment options with their healthcare team and to seek genetic counseling for further guidance on managing the condition.

Question 7

What are the potential complications of combined oxidative phosphorylation deficiency 51?

Accepted Answer

Combined oxidative phosphorylation deficiency 51 can lead to several complications due to its impact on multiple organ systems. These may include severe respiratory difficulties, such as respiratory failure and aspiration pneumonia, which can be life-threatening. Additionally, children may experience developmental regression, which affects their cognitive and motor skills, and may require ongoing support and intervention.

Question 8

How does combined oxidative phosphorylation deficiency 51 affect daily life for patients and their families?

Accepted Answer

Living with combined oxidative phosphorylation deficiency 51 can be challenging for both patients and their families. Children may need specialized care, including assistance with feeding through a nasogastric tube and support for developmental delays. Families often need to coordinate with a team of healthcare providers, including neurologists and nutritionists, to manage the child's health and ensure they receive the necessary support.

Question 9

What is the long-term prognosis for someone with combined oxidative phosphorylation deficiency 51?

Accepted Answer

The prognosis for combined oxidative phosphorylation deficiency 51 varies widely among individuals. While some may experience a period of stabilization after initial developmental regression, others may face ongoing challenges, including later motor decline. Access to specialized care and early intervention can significantly influence long-term outcomes, making it important for families to stay connected with healthcare professionals.

Question 10

What specialists should families consult for managing combined oxidative phosphorylation deficiency 51?

Accepted Answer

Families managing combined oxidative phosphorylation deficiency 51 should consult a multidisciplinary team of specialists. This team may include neurologists for neurological concerns, respiratory specialists for breathing difficulties, and nutritionists for feeding support. Regular check-ups with these experts can help monitor the child's condition and address any emerging issues, ensuring comprehensive care.

Research Type	Count	% of Total
Laboratory research	20	71%

Kisho

combined oxidative phosphorylation deficiency 51

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation deficiency 51

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 51?

What are the symptoms of combined oxidative phosphorylation deficiency 51?

What causes combined oxidative phosphorylation deficiency 51?

How is combined oxidative phosphorylation deficiency 51 inherited?

How is combined oxidative phosphorylation deficiency 51 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 51?

What are the potential complications of combined oxidative phosphorylation deficiency 51?

How does combined oxidative phosphorylation deficiency 51 affect daily life for patients and their families?

What is the long-term prognosis for someone with combined oxidative phosphorylation deficiency 51?

What specialists should families consult for managing combined oxidative phosphorylation deficiency 51?

Explore clinical features

Recent Publications